Seoul Pharma Co., Ltd (KOSDAQ:018680)
South Korea flag South Korea · Delayed Price · Currency is KRW
3,105.00
+40.00 (1.31%)
At close: Sep 29, 2025

Seoul Pharma Statistics

Total Valuation

Seoul Pharma has a market cap or net worth of KRW 36.20 billion. The enterprise value is 43.74 billion.

Market Cap36.20B
Enterprise Value 43.74B

Important Dates

Earnings Date n/a
Ex-Dividend Date n/a

Share Statistics

Seoul Pharma has 11.66 million shares outstanding.

Current Share Class 11.66M
Shares Outstanding 11.66M
Shares Change (YoY) n/a
Shares Change (QoQ) n/a
Owned by Insiders (%) n/a
Owned by Institutions (%) n/a
Float 4.73M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 0.69
PB Ratio 0.94
P/TBV Ratio 0.96
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 18.85, with an EV/FCF ratio of -10.16.

EV / Earnings -66.19
EV / Sales 0.84
EV / EBITDA 18.85
EV / EBIT n/a
EV / FCF -10.16

Financial Position

The company has a current ratio of 1.99, with a Debt / Equity ratio of 0.46.

Current Ratio 1.99
Quick Ratio 1.04
Debt / Equity 0.46
Debt / EBITDA 7.71
Debt / FCF -4.16
Interest Coverage -0.75

Financial Efficiency

Return on equity (ROE) is -1.69% and return on invested capital (ROIC) is -0.38%.

Return on Equity (ROE) -1.69%
Return on Assets (ROA) -0.29%
Return on Invested Capital (ROIC) -0.38%
Return on Capital Employed (ROCE) -0.59%
Revenue Per Employee 303.46M
Profits Per Employee -3.84M
Employee Count 172
Asset Turnover 0.74
Inventory Turnover 1.58

Taxes

Income Tax -84.70M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -16.37% in the last 52 weeks. The beta is 0.59, so Seoul Pharma's price volatility has been lower than the market average.

Beta (5Y) 0.59
52-Week Price Change -16.37%
50-Day Moving Average 3,286.70
200-Day Moving Average 3,350.73
Relative Strength Index (RSI) 28.68
Average Volume (20 Days) 7,441

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, Seoul Pharma had revenue of KRW 52.20 billion and -660.90 million in losses. Loss per share was -56.68.

Revenue52.20B
Gross Profit 31.83B
Operating Income -329.39M
Pretax Income -745.60M
Net Income -660.90M
EBITDA 2.32B
EBIT -329.39M
Loss Per Share -56.68
Full Income Statement

Balance Sheet

The company has 10.36 billion in cash and 17.90 billion in debt, giving a net cash position of -7.54 billion or -646.88 per share.

Cash & Cash Equivalents 10.36B
Total Debt 17.90B
Net Cash -7.54B
Net Cash Per Share -646.88
Equity (Book Value) 38.68B
Book Value Per Share 3,317.27
Working Capital 17.18B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -2.98 billion and capital expenditures -1.32 billion, giving a free cash flow of -4.31 billion.

Operating Cash Flow -2.98B
Capital Expenditures -1.32B
Free Cash Flow -4.31B
FCF Per Share -369.24
Full Cash Flow Statement

Margins

Gross margin is 60.98%, with operating and profit margins of -0.63% and -1.27%.

Gross Margin 60.98%
Operating Margin -0.63%
Pretax Margin -1.43%
Profit Margin -1.27%
EBITDA Margin 4.45%
EBIT Margin -0.63%
FCF Margin n/a

Dividends & Yields

Seoul Pharma does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield n/a
Shareholder Yield n/a
Earnings Yield -1.83%
FCF Yield -11.89%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

The last stock split was on April 12, 2004. It was a forward split with a ratio of 2.

Last Split Date Apr 12, 2004
Split Type Forward
Split Ratio 2

Scores

Seoul Pharma has an Altman Z-Score of 1.78 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 1.78
Piotroski F-Score 1